May 16th 2024
Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
July 18 - 20, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
7th Annual Live Medical Crossfire®: Hematologic Malignancies
View More
Low-Dose Amifostine May Prevent Platinum Neurotoxicity
March 1st 2002NEW YORK-Repeated low-dose administration of amifostine (Ethyol) is being studied in a randomized, multi-center, community-based trial in an attempt to prevent neurotoxicity caused by platinum-based chemotherapy.David Alberts, MD, and Martee Hensley, MD, discussed the new study at the Ethyol Emerging Neuropathy Trial Investigator Meeting.
Preop CT Identifies Unresectable Recurrent Ovarian Cancer
March 1st 2002CHICAGO-Preoperative helical computed tomography (CT) can improve the management of women with recurrent ovarian cancer by identifying disease that cannot be resected in secondary cytoreductive surgery, said Stacey A. Funt, MD, assistant attending radiologist, Memorial Sloan-Kettering Cancer Center.
Assessing the Total Cost of Chemotherapy-Induced Toxicities
March 1st 2002Chemotherapy-induced toxicities often adversely affect patients’ health and treatment plans, and can result in large costs for treatment and care. In addition to the costs associated with direct medical care, a large amount of indirect and out-of-pocket costs can be incurred.
Textbook of Medical Oncology, 2nd Edition
March 1st 2002In this day of encyclopedic oncology texts, frequently updated online reference sites, and literature searches at the click of a button, is there a place for a basic medical oncology textbook? The second edition of the Textbook of Medical Oncology, edited by Drs. Cavalli, Hansen, and Kaye, is approximately 50% longer than the first edition, due in large part to the inclusion of newer therapeutic approaches.
Oregovomab Is Promising as Ovarian Cancer Treatment
February 1st 2002NEW YORK-A monoclonal antibody with high affinity for an ovarian tumor-associated antigen has shown promising activity in preliminary results from a large phase III study, said Jonathan S. Berek, MD, chief of the Division of Gynecology
Adjuvant Chemotherapy Ups Survival in High-Risk Early Ovarian Cancer
February 1st 2002LISBON, Portugal-Adjuvant platinum-based chemotherapy significantly improves the outlook for women with high-risk early-stage epithelial ovarian cancer, according to the findings of two parallel, randomized phase III trials presented at the 11th European Cancer Conference (ECCO abstract 1019).
Current Status of Genetic Testing for Colorectal Cancer Susceptibility
February 1st 2002Solomon et al have written a valuable primer to guide clinicians in identifying, diagnosing, and treating familial colon cancer syndromes. The authors succinctly describe the essential features of each of the well-defined hereditary colon cancer syndromes, including those associated with colonic adenomas (hereditary nonpolyposis colorectal cancer [HNPCC] and familial adenomatous polyposis [FAP]) and colonic hamartomas (Peutz-Jeghers syndrome, juvenile polyposis, and Cowden syndrome). In addition to the specific features that might trigger recognition of one of these syndromes, we advise health-care providers to consider the possibility of hereditary cancer in cases with the following features:
Management of Patients at High Risk for Breast Cancer
January 1st 2002Management of Patients at High Risk for Breast Cancer, edited by Victor G. Vogel, MD, is designed for all physicians involved in breast cancer risk assessment and prevention. It does not assume a baseline familiarity with cancer risk
Race and Cancer Genetics: Lessons From BRCA1
January 1st 2002The effect of a patient’s race or ethnicity on cancer incidence and mortality rates remains a neglected area of cancer research. However, with cancer statistics differing among various populations, research on racial and ethnic groups could provide clues to cancer trends.
Modulation of Dose Intensity in Aerodigestive Tract Cancers: Strategies to Reduce Toxicity
December 1st 2001The population dynamics of cellular entry, traverse, and exit, through and from each phase of the cell cycle is coordinated throughout the day in the tissue of the human body. This coordination is particularly robust-ie, the daily peaks and valleys are particularly high and low-in tissues with the greatest average daily cellular proliferation. These tissues are also the most severely damaged by cancer treatments, most prominently cytotoxic drugs and ionizing irradiation.
Irinotecan Plus Cisplatin Used as First-Line Treatment of Ovarian Cancers
September 1st 2001NEW YORK CITY-Weekly irinotecan (Camptosar) and cisplatin (Platinol) can be successfully given as first-line treatment to women with advanced ovarian cancer. The toxicity is manageable, and some patients with suboptimally resected disease achieved an extended disease-free survival, David Spriggs, MD, reported. He is chief of the Developmental Chemotherapy Service at Memorial Sloan-Kettering Cancer Center in New York City.
Current Clinical Trials of Epothilone B Analog (BMS-247550)
September 1st 2001BMS-247550 is a methyl, semi-synthetic analog of the natural product epothilone B. Provided to the National Cancer Institute (NCI) by Bristol-Myers Squibb, BMS-247550 was chosen for clinical development because it demonstrated
Investigator-Initiated Health-Related Quality-of-Life Research
In part I of this series, we identified currently active clinical trials that include health-related quality-of-life (HRQOL) outcomes as a primary or secondary objective of the overall study (Trimble EL et al: ONCOLOGY 15:601-611, 2001). The goal of this
Researchers in Recurrent/Resistant Epithelial Ovarian Cancer Test Irinotecan
September 1st 2001HOUSTON, Texas-David M. Gershenson, MD, painted a bleak picture of current treatment for advanced ovarian cancer and suggested that new agents such as topoisomerase inhibitors should be studied further in clinical trials. Dr. Gershenson said that although CA-125 and transvaginal ultrasound are used for screening, they have limited efficacy, with the result that over 70% of ovarian cancers have already spread beyond the ovary by the time they are detected.
Chemotherapy Common at End of Life
July 1st 2001SAN FRANCISCO-More than four out of 10 cancer patients received chemotherapy during their last year of life, according to a study of Medicare patients in Massachusetts. Even a proportion of patients with tumors considered unresponsive to chemotherapy received treatments within 1 month of their death.
Levocarnitine Supplement Relieves Chemotherapy-Induced Fatigue
July 1st 2001SAN FRANCISCO-Preliminary data from an uncontrolled pilot study suggest that levocarnitine (L-Carnitine, Carnitor) supplementation can reduce fatigue in some patients. Francesco Graziano, MD, found that 87% of patients given levocarnitine 4 g/day po for 7 days reported reduced fatigue. Dr. Graziano is in the medical oncology department at the Hospital of Urbino, Italy.
Amifostine Supports Melphalan Dose Escalation in Stem Cell Transplantation
July 1st 2001SAN FRANCISCO-Amifostine (Ethyol) provided cytoprotection and allowed the maximum tolerated dose of melphalan (Alkeran) to be increased to 280 mg/m2 for cancer patients receiving autologous hematopoietic stem cell transplantation in a phase I and II study. Dose-limiting toxicity of melphalan was not able to be clearly determined from the trial, however, and might be higher, according to Gordon L. Phillips II, MD, director of the bone marrow transplantation program of the Greenebaum Cancer Center at the University of Maryland in Baltimore.
Risk of Breast and Ovarian Cancer in Women With Strong Family Histories
July 1st 2001Assessing the risk of breast and ovarian cancer starts with obtaining a complete and accurate family history. This can reveal evidence of inherited cancer risk. The highest risk of cancer is associated with germ-line abnormalities
Risk of Breast and Ovarian Cancer in Women With Strong Family Histories
July 1st 2001Assessing the risk of breast and ovarian cancer starts with obtaining a complete and accurate family history. This can reveal evidence of inherited cancer risk. The highest risk of cancer is associated with germ-line abnormalities
Risk of Breast and Ovarian Cancer in Women With Strong Family Histories
July 1st 2001Assessing the risk of breast and ovarian cancer starts with obtaining a complete and accurate family history. This can reveal evidence of inherited cancer risk. The highest risk of cancer is associated with germ-line abnormalities
Risk of Breast and Ovarian Cancer in Women With Strong Family Histories
July 1st 2001Assessing the risk of breast and ovarian cancer starts with obtaining a complete and accurate family history. This can reveal evidence of inherited cancer risk. The highest risk of cancer is associated with germ-line abnormalities
Epidermal Growth Factor Receptor Inhibitors in Clinical Trials
June 1st 2001With the understanding of the mechanism of malignant transformation has come the knowledge that oncogene products are frequently growth factors, growth factor receptors, or elements of growth factor signal-transduction pathways. Overexpression
Carboplatin/Docetaxel as First-Line Therapy for Gynecologic Cancers
June 1st 2001Combination chemotherapy with carboplatin (Paraplatin) and docetaxel (Taxotere) is a highly active and generally well-tolerated regimen when used as initial therapy for gynecologic cancers, including cancers of the ovary, fallopian tubes, and the
Health-Related Quality of Life in Cancer Clinical Trials
The Clinical Trials Referral Resource that appeared in the April issue of ONCOLOGY began a series on health-related quality of life (HRQOL). Part I of this series, which concludes this month, focuses on HRQOL questions in cancer treatment trials. Part II (on investigator-initiated HRQOL research) and part III (on HRQOL research as part of cancer prevention trials) will appear in upcoming issues. Information about these studies can be obtained from the contacts listed for each trial or from Edward L. Trimble, MD, MPH, at the Cancer Therapy Evaluation Program (CTEP), trimble@ctep.nci.nih.gov or (301) 496-1196